Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Apoth?ka Blockchain: Transforms Electronic Medical Records Platforms into Secure B...
Apoth?ka Blockchain: Transforms Electronic Medi...
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
BioSpecifics Technologies Corp. is a biopharmaceutical company that is the origina...
BioSpecifics Technologies Corp. is a biopharmac...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in ...
CNS Pharmaceuticals is a pre-clinical stage bio...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Join the National Investor Network and get the latest information with your interests in mind.